Anti-EGFRvIII CAR T-cell therapy (Duke University Medical Center)

N/A

Report date: 2025/01/26 16:34:26

Base Information

Drug NameAnti-EGFRvIII CAR T-cell therapy (Duke University Medical Center)
Drug Alias NameAnti-EGFRvIII CAR T cell therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionEpidermal growth factor receptor variant III antagonists
TargetsEpidermal growth factor receptor variant III
Therapy Area/IndicationsGliosarcomaGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSanbo Brain Hospital Capital Medical UniversityBeijing Marino Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDuke Cancer Institute
Active IndicationsN/A
Inactive IndicationsGliosarcomaGlioblastoma

Other Information

ATC CodeN/A
Related LinksN/A